CLRB Cellectar Biosciences Inc

$CLRB • Aggressive Acceleration: BTK inhibitors only manage the disease; once a patient develops a mutation or resistance (post-BTKi), the cancer accelerates aggressively. • Plunging Survival Rates: Without an effective subsequent therapy, the median survival for post-BTKi patients drops drastically to under a year. • The Clinical Answer: Cellectar’s Iopofosine I-131 addresses exactly this survival drop, delivering an exceptional 79.2% Major Response Rate in this terminal population.

$CLRB I don’t understand why this is trading like nobody wants it. I get the warrant heavy structure but if the trial results have any real merit, I’d expect a mid sized pharma to already be writing them a pocket money check. We’ll know when we know.

$CLRB revolutionary Phospholipid Drug Conjugate (PDC) technology provides high-precision oncology delivery by directly targeting cancer cell membranes while sparing healthy tissue. Fir example WaM efficency over 83.6% ORR, 61.8 % MRR, 100 % CBR💪💪💪 This highly versatile platform forms the basis for their crucial Phase 1b catalyst trial evaluating the Auger-emitting radioconjugate CLR 125. It brings remarkable new hope as a highly effective, tailored treatment for patients fighting refractory triple-negative breast cancer (TNBC) and validates the plattform immensly. 🍀🍀🍀🍀🚀🚀🚀

$CLRB • Blockbuster Efficacy: Exceptional 79.2% MRR in post-BTKi patients beats the global 61.8% baseline.🚀 • Deepening Responses: High probability of hitting ≥33% CR/VGPR on Oct 15 as data matures.🚀 • Massive Upside: Wall Street targets $11.50+, offering over 600% potential gains from $1.57.🚀 • Imminent Approval: Regulatory path clears the way for an FDA submission in mid-2027.🚀 • Takeover Target: Absurdly low $15.8M market cap makes it a prime acquisition for Big Pharma.🚀

$CLRB if the insiders don’t support this stock with market buys and management neither am I. Almost time to harvest this for tax season next year.

$CLRB I put my toes in the water with this god-awful dirty dog today. It's possible this company has set an all-time record for most reverse splits. This is about as long a shot as you can get....the company is immersed with shitty financing, convertible debt, preferred nightmares, warrants and a host of other exotic financing which is sure to dilute common shareholders upon any success. But at $1.84, I'll nibble.

$CLRB You don’t always have to take a Phase 2 winner all the way yourself. Sometimes the smarter move is to partner or sell once the data is good enough. Cellectar’s team gets this, I hope. They’re advancing the Phase 3 and NDA with new capital and the recent strong updates also make the asset more attractive to potential partners. It’s now about execution and timing, whether they stay independent or find the right deal.

$CLRB Certainly looks like more than a gift now. Somebody, or a bunch of somebodies, will likely start loading in advance of an FDA meeting. Buy low, sell high right?

$CLRB glad I bought spacex. Management needs to address this issue. Always delays and dilution. Not buying anymore of this pos either way. May even sell. It’s clear that they don’t care about the shareholders.

$CLRB Looking at it and trying to understand the current sentiment. 1. Company guided for an EMA CMA filing in Q3 2026. That quarter has closed with no announcement that the filing was submitted. 2. U.S. NDA timeline is now 1H 2027 with first patient dosing in the confirmatory Phase 3 targeted for early 2027. 3. Cash runway guided into Q2 2027, which means additional capital will likely be required to fund the Phase 3 and regulatory work. 4. Timeline adjustments have occurred more than once. At the same time, the company still holds what look like meaningful assets: 1. Phase 2 CLOVER-WaM data in heavily pretreated / post-BTKi WM showing solid response rates and durability. 2. FDA Breakthrough Therapy Designation, Fast Track and Orphan designations plus EMA PRIME designation and positive SAWP feedback supporting a CMA pathway. 3. Proprietary PDC platform with additional earlier stage programs (including CLR 125 in TNBC).

$CLRB $ 1.46 😆 another reverse split in making. Try to short this pig 🐖 @ $ 3.00. Its said you need extra margin for this. Only people make money out of this bio scams are people who run this kind of scam and brokers. Stay away.....

$CLRB Rather strange seeing this $PFSA going up a bunch on nothing when it was CLRB with those good trial results this morning. Oh well. Misplaced exuberance.

$CLRB this company has been making the same promises to investors for 10 years. Meanwhile the stock is down 99.9999999999%. It’s over Johnny

$CLRB what do the people who work at this company do all day? Such a bizarre dead stock

$CLRB it's a bit weird. It seems like the EMA submission in now dependant on the US submission, that is, it's now a second lien matter. At least this is what I gathered from the October corporate presentation. If that is correct, all future warrants are tied only to US milestones.

$CLRB slowly loading today looking to swing. Can't go straight down forever, and no urgent dilution necessary with all the cash they have on balance sheet.

$CLRB Haven’t heard any mention of the triple negative breast cancer phase 1b CL 125 trial. As far as I can tell they’re still recruiting so I guess no news is good news.

$CLRB I've been holding this waiting for good news but I think it's time to dump this turd....

$CLRB starting to get a bit upset over zero positive news. What’s going on. We good? Am i just loosing patience?

$CLRB See this $JAGX today? The news they received their FDA PDUFA waivers? And the stock from $2 to $66 tonite? Same waiver CLRB is waiting for that will likely come quickly since CLRB is an "only" provider worldwide.